A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and efficacy of two doses of MAP0010
versus placebo in asthmatic infants and children, 12 months to 8 years of age, over a 12-week
treatment period.
Phase:
Phase 3
Details
Lead Sponsor:
Allergan
Collaborator:
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan